Vocabria Tablet, Film Coated
NDC 49702-248
Product Information
Vocabria (cabotegravir sodium) is a NDA-approved product labeled by Viiv Healthcare Company. This medication is typically used as a hiv integrase inhibitors [moa]. It is supplied as a white tablet, film coated for oral administration. This product entry covers the primary NDC 49702-248 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
SV;CTV
Code Structure Chart
Product Details
What is NDC 49702-248?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CABOTEGRAVIR SODIUM (UNII: 3L12PT535M)
- CABOTEGRAVIR (UNII: HMH0132Z1Q) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2475199 - cabotegravir 30 MG Oral Tablet
- RxCUI: 2475199 - cabotegravir 30 MG (as cabotegravir sodium 31.62 MG) Oral Tablet
- RxCUI: 2475205 - VOCABRIA 30 MG Oral Tablet
- RxCUI: 2475205 - cabotegravir 30 MG Oral Tablet [Vocabria]
- RxCUI: 2475205 - Vocabria 30 MG (as cabotegravir sodium 31.62 MG) Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Cabotegravir
Cabotegravir is used along with rilpivirine (Edurant) as a short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older weighing at least 77 pounds (35 kg). Cabotegravir is used as a short-term prevention of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older wighing at least 77 pounds (35 kg). It is used to see if the body can tolerate cabotegravir before receiving the cabotegravir injection and in certain cases of missed doses of cabotegravir injection. Cabotegravir is in a class of medications called HIV integrase inhibitors. It works by decreasing the amount of HIV in the blood. Although cabotegravir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
[Learn More]
* Please review the full disclaimer at the bottom of this page.